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Concomitant Genetic Alterations With Response to Treatment and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With EGFRMutant Advanced Non-Small Cell Lung Cancer
Treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) demonstrates superior efficacy, compared with chemotherapy, for patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC). 1 However, approximately 20% to 30% of patients who receive such treatment exhibit de novo resistance to therapy with EGFR TKIs. 2 A better understanding of the underlying mechanisms of this phenomenon is imperative to optimize clinical outcomes.
Methods | This retrospective cohort study (conducted from January 1, 2012, to April 30, 2014) included 58 patients with metastatic NSCLC associated with EGFR (OMIM 131550) mutation (determined in tumor tissue) treated with first-line EGFR TKIs. The institutional review board of Sun Yat-sen University Cancer Center approved the study, and all of the patients provided written informed consent. Cell-free DNA obtained before treatment was subjected to next-generation sequencing of 49 cancer-related genes with use of a kit (Ion Pi Sequencing 200 kit v2; Thermo Fisher Scientific), as reported elsewhere, at a mean depth of 15 370X. 3 The association between response and concomitant mutation was determined by logistic regression analysis. Data were analyzed from April 30 through November 30, 2017. Kaplan-Meier survival curves and Cox proportional hazards regression analysis were performed, and hazard ratios (HRs) and 95% CIs were calculated to determine the survival difference. Statistical significance was defined as a 2-sided P < .05.
Results | Among the 58 patients, the median age was 58. (Figure, A) .
Concomitant mutation was significantly associated with reduced objective response rate (44% vs 77%; P = .01), shorter duration of progression-free survival ( Figure, B (Table) .
Discussion | Similar to a recent study, our results might challenge the current view that EGFR-mutant NSCLC is a singleoncogene-driven disease. 4 This study also reveals the widespread existence of concomitant mutations in patients with EGFR-mutant advanced NSCLC. In addition, genetic coalterations negatively affect the response and survival of patients who receive first-line treatment with EGFR TKIs, plausibly because of the bypass activation of survival signaling pathways or tumor heterogeneity. Patients with EGFR exon 19 deletion were found to have longer survival than those with exon 21 mutation, although the underlying mechanisms remain unknown. 5 Of interest, we found that patients with exon 21 mutation had a significantly higher incidence of concomitant mutation. In multivariable analysis, the EGFR subtype was no longer significantly associated with survival, which suggests that the inferior treatment outcome associated with exon 21 mutation could be attributed to or confounded by the higher incidence of concomitant mutation. The presence of EGFR T790M mutation at baseline also was associated with poorer efficacy of first-generation EGFR TKIs, which provides a rationale for the superiority of osimeritinib therapy over therapy with earlier-generation TKIs in untreated EGFRmutant NSCLC.
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Major limitations of this study were the sample size, the single-centered design, and the lack of serial biopsies. In addition, the data from our hot spot next-generation sequencing (not including other mutations, copy number alterations, or chromosomal abnormalities) might represent an underestimation of concomitant mutation and prevent an in-depth analysis of signaling pathway or clonality.
These limitations aside, our results suggest that the common presence of co-occurring genetic alterations may be associated with resistance to EGFR TKIs in patients with Letters EGFR-mutant NSCLC. Our study highlights the importance of deploying multiplex molecular profiling and conducting research on the use of polytherapy or sequential therapy to address the coalterations that drive drug resistance. 
COMMENT & RESPONSE The Paradigm of Escalation of Commitment in Treatment Decisions Near the End of Life
To the Editor A thorough discussion of "commitment escalation" in treatment decisions near the end of life details a wise and timely approach to patient-centered care. In addition to providing, as the authors conclude, "a better prognostic disease perception" 1 that tends to lead to less aggressive treatment, such specialist-level involvement by a palliative care team brings wider collateral benefit to the patient, family, and staff. Consistent and early attention to virtually all patients' most common physical, emotional, and spiritual needs allows for an easier transition to long-term survivorship care in the same way it does to end-of-life care. 2, 3 It is no longer necessary to wait until a patient demonstrates a refractory response to treatment to say, "Now we will focus our attention on maintaining your quality of life and comfort." Enriched attention to pain, fatigue, nutrition, activity, and education throughout care is as fundamental a component of "patient-centered care" as are the recommendations for surgery, chemotherapy, radiation therapy, hormonal therapy, and targeted personalized agents.
Stewart B. Fleishman, MD
To the Editor Knoops and Bastin 1 focus on an important population of patients who have hematological malignant neoplasms with uncertain prognoses and a high chance of suffering from distressing symptoms during the course of their cancer and treatment. Their description of "escalation of commitment" is a fitting paradigm in this population and with this patient-physician dyad. They recommend several strategies to defend against this bias, including clinician self-reflection, discussing risk of treatment failure and alternative approaches even before starting disease modifying therapy, and finally involving a third party such as a palliative care specialist.
We believe it is important to include communication training and strategies as part of clinical training to facilitate the discussions they recommend and minimize the effect of such psychological habits and biases on treatment decisions. In general, these approaches emphasize discussions over time with revision of prognosis as more information becomes available to avoid anchoring bias. 2 For example, an oncologist may say, "I think we're in a different place now, compared with our last discussion" (ie, Reframe from the REMAP paradigm) 3 or "Although I hope another line of therapy may accomplish a cure, I worry that chances have dropped dramatically" (ie, Sharing Prognosis from the Serious Illness Conversation Guide). 4 In addition, these strategies elicit hopes other than cure; most people do not want to live longer just to live longer-they have things they want to do or experience with the time they have. These strategies also give space for expression of fears and worries, critical abilities, and trade-offs from the patient's perspective. Having this understanding of the patient's perspective allows the physician and patient to arrive at realistically achievable outcomes at each stage of the illness driven by the patient's preferences (both through pursuit of desirable outcomes and efforts to avoid undesirable ones). This enables patients' values to inform treatment recommendations, rather than anchoring treatment decisions on an ever-receding goal of cure with the assumption that the patient would accept the downsides of aggressive therapy. Consulting a palliative care specialist for all patients with hematologic malignant neoplasms to fill this communication training gap is not possible given the shortage of hospice and palliative medicine workforce. 5 Although ensuring that every practicing oncologist is trained in these communication best practices is a far-reaching goal, it has the potential to improve care for every patient with a diagnosis of a hematologic malignant neoplasm, making it a worthwhile effort.
Maxwell T. Vergo, MD Amelia M. Cullinan, MD Matthew Wilson, MD
